For Immediate Release
Chicago, IL – August 1, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis AG (
NVS Quick Quote NVS - Free Report) , Duke Energy Corp. ( DUK Quick Quote DUK - Free Report) , Boston Scientific Corp. ( BSX Quick Quote BSX - Free Report) , Norfolk Southern Corp. ( NSC Quick Quote NSC - Free Report) and Cadence Design Systems, Inc. ( CDNS Quick Quote CDNS - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Analyst Reports for Novartis, Duke Energy and Boston Scientific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis AG , Duke Energy Corp., and Boston Scientific Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>> Novartis shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+21.0% vs. -3.0%). The company's second quarter performance was good on improvement in the lagging Sandoz business and cardiovascular drug Entresto's momentum. Sandoz's performance was driven by growth in Europe on both launches and the recovery of the healthcare systems.
Consequently, the company also raised the full-year guidance for Sandoz. Drugs like Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio should continue to fuel growth and offset the impact of generic competition. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost performance further.
The pipeline progress is impressive, and the company has some promising candidates. However, generic competition for key drugs and pipeline setbacks pose concerns.
) read the full research report on Novartis here >>> Duke Energy shares have outperformed the Zacks Utility - Electric Power industry over the year-to-date basis (+5.8% vs. +2.3%). The company is a premier utility service provider that invests heavily in infrastructure and expansion projects. During the 2022-2026 period, it projects to spend the capital of $63 billion, while $130 billion over the next decade.
It has lowered its carbon emissions by 44% since 2005 and is now expanding its 2050 net-zero goals to include Scope 2 and certain Scope 3 emissions. It expects project load growth to increase nearly 1.5% in 2022. Yet, its ability to achieve a net-zero target by 2050 at a cost-effective price could be at risk due to higher technological resources prices.
Also, the fluctuating energy prices may impact its results. A comparative analysis of its trailing 12-month Enterprise Value/Sales ratio shows a gloomy picture that may concern investors.
) read the full research report on Duke Energy here >>> Boston Scientific shares have declined -9.7% over the past year against the Zacks Medical - Products industry's decline of -29.0%. The company's mounting costs and expenses are putting pressure on its margins. The ongoing macro-environment challenges related to increasing freight costs and higher direct labor wages continue to hamper business. Unfavorable foreign exchange deters growth. The upper end of the full-year adjusted EPS guidance has been reduced increasing concerns.
However, Boston Scientific ended the second quarter of 2022 on a bullish note with adjusted earnings and revenues surpassing the Zacks Consensus Estimate. The company registered a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem. Organic revenues at each of its core business and geographies were up. The raised 2022 organic revenue guidance looks promising.
) read the full research report on Boston Scientific here >>>
Other noteworthy reports we are featuring today include Norfolk Southern Corp. and Cadence Design Systems, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.